Nihal El Rouby

1.1k total citations · 1 hit paper
24 papers, 617 citations indexed

About

Nihal El Rouby is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Nihal El Rouby has authored 24 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 8 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Nihal El Rouby's work include Pharmacogenetics and Drug Metabolism (10 papers), Genetic Associations and Epidemiology (6 papers) and Diabetes Treatment and Management (4 papers). Nihal El Rouby is often cited by papers focused on Pharmacogenetics and Drug Metabolism (10 papers), Genetic Associations and Epidemiology (6 papers) and Diabetes Treatment and Management (4 papers). Nihal El Rouby collaborates with scholars based in United States, Japan and China. Nihal El Rouby's co-authors include Julie A. Johnson, John J. Lima, Katherine E. Santostefano, Naohiro Terada, Rhonda M. Cooper‐DeHoff, Larisa H. Cavallari, Natalie C. Fredette, Takashi Hamazaki, Stuart A. Scott and David Thacker and has published in prestigious journals such as Stem Cells, Clinical Pharmacology & Therapeutics and Frontiers in Pharmacology.

In The Last Decade

Nihal El Rouby

22 papers receiving 603 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing

2020 194 citations John J. Lima, Cameron D. Thomas et al. Clinical Pharmacology & Therapeutics profile →

Peers

Countries citing papers authored by Nihal El Rouby

Since Specialization

Citations

This map shows the geographic impact of Nihal El Rouby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nihal El Rouby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nihal El Rouby more than expected).

Fields of papers citing papers by Nihal El Rouby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nihal El Rouby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nihal El Rouby. The network helps show where Nihal El Rouby may publish in the future.

Co-authorship network of co-authors of Nihal El Rouby

This figure shows the co-authorship network connecting the top 25 collaborators of Nihal El Rouby. A scholar is included among the top collaborators of Nihal El Rouby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nihal El Rouby. Nihal El Rouby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multi‐Gene Pharmacogenomic Testing in a Community‐Based Setting Is Feasible and Reduces Total Healthcare Costs 2025 ·Clinical and Translational Science ·Nihal El Rouby, Josiah D. Allen, (unknown), Peter McIntyre, (unknown), A. Ramesh, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), A.M. Schumann, (unknown), (unknown), (unknown)	0
2	Genome Wide Association Study (GWAS) Identifies Novel Genetic Loci for Second‐Generation Antipsychotics (SGA)‐Induced Metabolic Syndrome (MetS) 2025 ·Clinical and Translational Science ·Nihal El Rouby, (unknown), Michael Preuß, Simon Lee, Mingjian Shi, Rajiv Nadukuru, Sara L. Van Driest, Jonathan D. Mosley, Melissa P. DelBello	0
3	A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), D. Max Smith, Christina L. Aquilante, Emily J. Cicali, Nihal El Rouby, Daniel L. Hertz, Iman Imanirad, Jai N. Patel, Stuart A. Scott, Sandra M. Swain, Sony Tuteja, J. Kevin Hicks	2
4	Genome‐wide associations with metabolic syndrome among UK Biobank participants reporting use of second‐generation antipsychotics 2025 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Nihal El Rouby, (unknown), Michael Preuß, Simon Lee, Mingjian Shi, (unknown), Lisa J. Martin, Bahram Namjou‐Khales, Leah C. Kottyan, Sara L. Van Driest, Jonathan D. Mosley, Melissa P. DelBello	1
5	Pharmacogenomics polygenic risk score: Ready or not for prime time? 2024 ·Clinical and Translational Science ·(unknown), Gabriele Stocco, Katherine N. Theken, Alyson L. Dickson, QiPing Feng, Jason H. Karnes, Jonathan D. Mosley, Nihal El Rouby	7
6	Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center 2024 ·Clinical and Translational Science ·(unknown), (unknown), (unknown), (unknown), (unknown), Josiah D. Allen, (unknown), (unknown), (unknown), (unknown), Nihal El Rouby	5
7	Important preparatory steps and clinical considerations for pharmacogenetics adoption into practice 2021 ·Aniwaa Owusu Obeng, Nihal El Rouby, (unknown), (unknown)	2
8	Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans 2021 ·Frontiers in Pharmacology ·Heidi E. Steiner, (unknown), (unknown), (unknown), Nihal El Rouby, (unknown), (unknown), (unknown), (unknown), Carlos‐Alberto Calderón‐Ospina, Xiaoxiao Sun, Mara Helena Hutz, Stuart A. Scott, Larisa H. Cavallari, Dora Janeth Fonseca, Jorgé Duconge, Mariana Rodrigues Botton, Paulo Caleb Júnior Lima Santos, Jason H. Karnes	16
9	Genomewide association analysis of warfarin dose requirements in Middle Eastern and North African populations 2021 ·Clinical and Translational Science ·Nihal El Rouby, Mohamed H. Shahin, (unknown), Sherief Khalifa, Hazem Elewa	11
10	Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection 2020 ·Genetics in Medicine ·Amber L. Beitelshees, James M. Stevenson, Nihal El Rouby, Chrisly Dillon, Philip E. Empey, Elliot M. Fielstein, Julie A. Johnson, Nita A. Limdi, Henry H. Ong, Francesco Franchi, Dominick J. Angiolillo, (unknown), Marc B. Rosenman, Todd C. Skaar, Sony Tuteja, Larisa H. Cavallari	8
11	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing breakdown → 2020 ·Clinical Pharmacology & Therapeutics ·John J. Lima, Cameron D. Thomas, Julia M. Barbarino, Zeruesenay Desta, Sara L. Van Driest, Nihal El Rouby, Julie A. Johnson, Larisa H. Cavallari, Valentina Shakhnovich, David Thacker, Stuart A. Scott, Matthias Schwab, Chakradhara Rao S. Uppugunduri, Christine M. Formea, James P. Franciosi, Katrin Sangkuhl, Andrea Gaedigk, Teri E. Klein, Roseann S. Gammal, Takahisa Furuta	194
12	Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel 2019 ·Genetic Testing and Molecular Biomarkers ·Taimour Langaee, Nihal El Rouby, (unknown), (unknown), Larisa H. Cavallari	3
13	Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta‐Blockers in European Americans 2019 ·Clinical and Translational Science ·(unknown), Nihal El Rouby, Caitrin W. McDonough, Yan Gong, Kent R. Bailey, Eric Boerwinkle, Arlene B. Chapman, John G. Gums, Stephen T. Turner, Rhonda M. Cooper‐DeHoff, Julie A. Johnson	11
14	Evaluation of FDA Boxed Warning on Prescribing Patterns of Fluoroquinolones for Uncomplicated Urinary Tract Infections 2019 ·Annals of Pharmacotherapy ·Kevin Cowart, (unknown), Nihal El Rouby, (unknown)	22
15	Genome-wide association analysis of common genetic variants of resistant hypertension 2018 ·The Pharmacogenomics Journal ·(unknown), Nihal El Rouby, Caitrin W. McDonough, Yan Gong, Leslie A. McClure, Braxton D. Mitchell, Richard B. Horenstein, Robert L. Talbert, Dana C. Crawford, Matthew A. Gitzendanner, Atsushi Takahashi, Toshihiro Tanaka, Michiaki Kubo, Carl J. Pepine, Rhonda M. Cooper‐DeHoff, Oscar Benavente, Alan R. Shuldiner, Julie A. Johnson	16
16	Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine 2018 ·Expert Opinion on Drug Metabolism & Toxicology ·Nihal El Rouby, John J. Lima, Julie A. Johnson	172
17	Concise Review: Induced Pluripotent Stem Cell Research in the Era of Precision Medicine 2017 ·Stem Cells ·Takashi Hamazaki, Nihal El Rouby, Natalie C. Fredette, Katherine E. Santostefano, Naohiro Terada	59
18	Genetics of Resistant Hypertension: a Novel Pharmacogenomics Phenotype 2015 ·Current Hypertension Reports ·Nihal El Rouby, Rhonda M. Cooper‐DeHoff	14
19	Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics 2015 ·Stem Cells Translational Medicine ·(unknown), Katherine E. Santostefano, (unknown), Nihal El Rouby, (unknown), Chelsey S. Simmons, Mahito Nakanishi, Rhonda M. Cooper‐DeHoff, Julie A. Johnson, Naohiro Terada	35
20	The influence of the CYP2C1910 allele on clopidogrel activation and CYP2C192 genotyping 2014 ·Pharmacogenetics and Genomics ·Taimour Langaee, Hao‐Jie Zhu, Xinwen Wang, Nihal El Rouby, John S. Markowitz, Joyce A. Goldstein, Julie A. Johnson	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact